The results confirmed in vivo the significant reduction of xenograft tumor volume and weight in mice treated with casticin only, or agomir-148a-3p only, the reduction of DNMT1 activity and mRNA levels, and the reduction of the stemness biomarker CD44 expression. This evidence concerns the gene CD44 and neoplasm.